Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses

Aneesh Chandran, Joshua Rosenheim, Gayathrie Nageswaran, Leo Swadling, View ORCID ProfileGabriele Pollara, View ORCID ProfileRishi K Gupta, View ORCID ProfileJose Afonso Guerra-Assuncao, Annemarie Woolston, Tahel Ronel, Corrina Pade, Joseph Gibbons, Blanca Sanz-Magallon Duque De Estrada, Marc Robert de Massy, Matthew Whelan, Amanda Semper, Tim Brooks, Daniel M Altmann, Rosemary J Boyton, Áine McKnight, Charlotte Manisty, Thomas Alexander Treibel, James Moon, View ORCID ProfileGillian S Tomlinson, Mala K Maini, Benjamin M Chain, View ORCID ProfileMahdad Noursadeghi, COVIDsortium Investigators
doi: https://doi.org/10.1101/2021.03.30.21254540
Aneesh Chandran
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Rosenheim
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gayathrie Nageswaran
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Swadling
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriele Pollara
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriele Pollara
Rishi K Gupta
2Institute for Global Health, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rishi K Gupta
Jose Afonso Guerra-Assuncao
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jose Afonso Guerra-Assuncao
Annemarie Woolston
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahel Ronel
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corrina Pade
3Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Gibbons
3Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blanca Sanz-Magallon Duque De Estrada
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Robert de Massy
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Whelan
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Semper
4National Infection Service, Public Health England, Porton Down, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Brooks
4National Infection Service, Public Health England, Porton Down, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M Altmann
5Department of Immunology and Inflammation, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosemary J Boyton
6Department of Infectious Disease, Imperial College London, London, UK
7Lung Division, Royal Brompton Harefield Hospitals, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Áine McKnight
3Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Manisty
8Institute of Cardiovascular Sciences, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Alexander Treibel
8Institute of Cardiovascular Sciences, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Moon
8Institute of Cardiovascular Sciences, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian S Tomlinson
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gillian S Tomlinson
Mala K Maini
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin M Chain
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahdad Noursadeghi
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mahdad Noursadeghi
  • For correspondence: m.noursadeghi@ucl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The correlates of natural protective immunity to SARS-CoV-2 in the majority who experience asymptomatic infection or non-severe disease are not fully characterised, and remain important as new variants emerge. We addressed this question using blood transcriptomics, multiparameter flow cytometry and T cell receptor (TCR) sequencing spanning the time of incident infection. We identified a type 1 interferon (IFN) response common to other acute respiratory viruses, and a cell proliferation response that discriminated SARS-CoV-2 from other viruses. These responses peaked by the time the virus was first detected, and in some preceded virus detection. Cell proliferation was most evident in CD8 T cells and associated with rapid expansion of SARS-CoV-2 reactive TCRs. We found an equally rapid increase in immunoglobulin transcripts, but circulating virus-specific antibodies lagged by 1-2 weeks. Our data support a protective role for rapid induction of type 1 IFN and CD8 T cell responses to SARS-CoV-2.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding for COVIDsortium was donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Citadel and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. RKG is funded by National Institute for Health Research (DRF-2018-11-ST2-004). JCM, CM, and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres, and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223). TAT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. RJB/DMA are supported by UKRI/MRC Newton (MR/S019553/1, MR/R02622X/1, MR/V036939/1MR/S019553/1, and MR/R02622X/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC, and Horizon 2020 Marie Curie Actions. MKM is supported by the UKRI/NIHR UK-CIC grant, a Wellcome Trust Investigator Award (214191/Z/18/Z), and a CRUK Immunology grant (26603) AM is supported by Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew Hospital Trust. Funders had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit for publication. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by a UK Research Ethics Committee (South Central - Oxford A Research Ethics Committee, reference 20/SC/0149). All participants provided written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Correction to author name.

Data Availability

Open access to RNAseq and TCRseq data and associated essential metadata will be made available after peer-reviewed publication. Applications for access to the individual participant de-identified data (including data dictionaries) and samples can be made to the access committee via an online application https://covid-consortium.com/application-for-samples/. Each application will be reviewed, with decisions to approve or reject an application for access made on the basis of (i) accordance with participant consent and alignment to the study objectives (ii) evidence for the capability of the applicant to undertake the specified research and (iii) availability of the requested samples. The use of all samples and data will be limited to the approved application for access and stipulated in the material and data transfer agreements between participating sites and investigators requesting access.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses
Aneesh Chandran, Joshua Rosenheim, Gayathrie Nageswaran, Leo Swadling, Gabriele Pollara, Rishi K Gupta, Jose Afonso Guerra-Assuncao, Annemarie Woolston, Tahel Ronel, Corrina Pade, Joseph Gibbons, Blanca Sanz-Magallon Duque De Estrada, Marc Robert de Massy, Matthew Whelan, Amanda Semper, Tim Brooks, Daniel M Altmann, Rosemary J Boyton, Áine McKnight, Charlotte Manisty, Thomas Alexander Treibel, James Moon, Gillian S Tomlinson, Mala K Maini, Benjamin M Chain, Mahdad Noursadeghi, COVIDsortium Investigators
medRxiv 2021.03.30.21254540; doi: https://doi.org/10.1101/2021.03.30.21254540
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses
Aneesh Chandran, Joshua Rosenheim, Gayathrie Nageswaran, Leo Swadling, Gabriele Pollara, Rishi K Gupta, Jose Afonso Guerra-Assuncao, Annemarie Woolston, Tahel Ronel, Corrina Pade, Joseph Gibbons, Blanca Sanz-Magallon Duque De Estrada, Marc Robert de Massy, Matthew Whelan, Amanda Semper, Tim Brooks, Daniel M Altmann, Rosemary J Boyton, Áine McKnight, Charlotte Manisty, Thomas Alexander Treibel, James Moon, Gillian S Tomlinson, Mala K Maini, Benjamin M Chain, Mahdad Noursadeghi, COVIDsortium Investigators
medRxiv 2021.03.30.21254540; doi: https://doi.org/10.1101/2021.03.30.21254540

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)